The theme of this ongoing R01 project is that risk factors for Alzheimer's disease (AD) are associated with presymptomatic changes in brain function that can be detected well in advance of symptom onset. Previously we studied an AD risk cohort known as the Wisconsin Registry for Alzheimer's Prevention (WRAP) and have shown functional MRI (fMRI) associated changes due to family history of AD and apolipoprotein E genotype. In this project we will investigate associations that may shed light on explanatory mechanisms of our previously observed findings by measuring amyloid burden using [C11]PiB, regional cerebral metabolic rate of glucose (rCMRglu) using [F18]fluoro-deoxyglucose (FDG) positron emission tomography (PET), neural function, rate of atrophy and ischemic lesion burden using MRI. Our prior study had a cross-sectional design;thus, a second major goal is to investigate the longitudinal course of brain change in a group of at risk subjects who were cognitively normal at baseline;some are now declining toward MCI. This proposed ongoing project represents a unique opportunity to comprehensively follow high-risk patients from cognitively normal to pre-MCI, and eventually to MCI and AD. Our studies are centered around three Specific Aims: A) to examine potential mechanisms (by way of association) of the BOLD risk effect we have observed in the prior funding period;B) To investigate longitudinal presymptomatic evolution of AD related brain changes and cognitive decline in people who are at high risk for AD, and determine whether PiB predicts decline in people at risk;C) Examine the direct relationship between brain changes and the best available known biomarkers consisting of CSF A242, t-tau and p-tau181. We will study 250 subjects longitudinally and use integrated path and regression analyses to accomplish these cross-sectional and longitudinal aims.

Public Health Relevance

By the time a patient exhibits symptomatic dementia, devastating neural loss has already occurred, and the time window for most effective intervention already past. If a preclinical signal can be reliably observed and is predictive of cognitive decline, this will greatly strengthen the rationale for earlier intervention rather than waiting for symptomatic AD to present itself.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-BDCN-N (02))
Program Officer
Hsiao, John
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Wisconsin Madison
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Dougherty, Ryan J; Schultz, Stephanie A; Boots, Elizabeth A et al. (2017) Relationships between cardiorespiratory fitness, hippocampal volume, and episodic memory in a population at risk for Alzheimer's disease. Brain Behav 7:e00625
Dean 3rd, Douglas C; Hurley, Samuel A; Kecskemeti, Steven R et al. (2017) Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease. JAMA Neurol 74:41-49
Sprecher, Kate E; Koscik, Rebecca L; Carlsson, Cynthia M et al. (2017) Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. Neurology 89:445-453
Casaletto, Kaitlin B; Elahi, Fanny M; Bettcher, Brianne M et al. (2017) Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers. Neurology 89:1782-1788
Racine, Annie M; Merluzzi, Andrew P; Adluru, Nagesh et al. (2017) Association of longitudinal white matter degeneration and cerebrospinal fluid biomarkers of neurodegeneration, inflammation and Alzheimer's disease in late-middle-aged adults. Brain Imaging Behav :
Dougherty, Ryan J; Schultz, Stephanie A; Kirby, Taylor K et al. (2017) Moderate Physical Activity is Associated with Cerebral Glucose Metabolism in Adults at Risk for Alzheimer's Disease. J Alzheimers Dis 58:1089-1097
Law, Lena L; Schultz, Stephanie A; Boots, Elizabeth A et al. (2017) Chronotropic Response and Cognitive Function in a Cohort at Risk for Alzheimer's Disease. J Alzheimers Dis 56:351-359
Betthauser, Tobey J; Lao, Patrick J; Murali, Dhanabalan et al. (2017) In Vivo Comparison of Tau Radioligands 18F-THK-5351 and 18F-THK-5317. J Nucl Med 58:996-1002
Vogt, Nicholas M; Kerby, Robert L; Dill-McFarland, Kimberly A et al. (2017) Gut microbiome alterations in Alzheimer's disease. Sci Rep 7:13537
Betthauser, Tobey J; Ellison, Paul A; Murali, Dhanabalan et al. (2017) Characterization of the radiosynthesis and purification of [18F]THK-5351, a PET ligand for neurofibrillary tau. Appl Radiat Isot 130:230-237

Showing the most recent 10 out of 100 publications